002317.SZ
众生药业
SZSE · Healthcare · C 制造业 · CN
CNY 25.34
−3.17%Sep 4, 2026, 09:44 UTC
Zhongsheng Pharmaceutical provided a joint liability guarantee of 200 million yuan for its wholly-owned subsidiary Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd. for a comprehensive credit line from Bank of Communications Dongguan Branch.
Source:Sep 4, 2026, 09:44 UTC
Zhongsheng Pharmaceutical received approval from China's National Medical Products Administration to add a 0.2g specification of its fenofibrate capsules, deemed consistent with generic drug quality and efficacy.
Source:Sep 2, 2026, 09:52 UTC
Zhongsheng Pharmaceutical's subsidiary Guangdong Zhongsheng Ruichuang Biotech received NMPA acceptance of its clinical trial application for a new indication of Anguradvir tablets to treat high-risk influenza A, planning a Phase III study.
Source:Aug 17, 2026, 10:55 UTC
Zhongsheng Pharmaceutical announced on August 17, 2026 that it will acquire a 12.06% stake in its subsidiary Guangdong Zhongsheng Ruichuang Biotech from three shareholders for $28.2621 million, increasing its ownership from 77.12% to 89.18%.
Source:Jul 31, 2026, 09:09 UTC
Zhongsheng Pharmaceutical's wholly-owned subsidiary Guangdong Xianqiang Pharmaceutical received approval from the National Medical Products Administration for the registration of its brexpiprazole API for market launch.
Source: